PASADENA, Calif.-(BUSINESS WIRE)---- Sarwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that yesterday it filed a Complaint for Declaratory Judgment in the United States District Court for the District of Delaware against Ionis Pharmaceuticals, Inc., to declare that Ionis's United States Patent No. 9,593,333 ("the '333 patent† ) is invalid and not infringed by Arrowhead's planned commercialization of investigational plozasiran, which is under FDA review. Arrowhead intends to vigorously. ...